Intraperitoneal octenidindihydro-chloride - phenoxyethanol solution to prevent peritoneal adhesion formation in a rat peritonitis model.
BACKGROUND
Peritoneal adhesion is a common complication following abdominal surgery. Despite recent advances in diagnosis and treatment, it still presents a problem for the patients and surgeons. In the present study, we investigated the effects of octenidindihydro-chloride - phenoxyethanol (OCP) on peritoneal adhesions.


METHODS
Rats were divided into four groups: Group 1 (saline), Group 2 (peritonitis plus saline), Group 3 (OCP), and Group 4 (peritonitis plus OCP). Peritonitis was induced in the rats of Groups 2 and 4. The abdominal cavities of the rats in Groups 1 and 2 were washed with saline, while those of the rats in Groups 3 and 4 were irrigated with 1:10 OCP solution. Adhesion and fibrotic scores were determined by re-laparotomy after 21 days.


RESULTS
The adhesion scores in Groups 1 (saline), 2 (peritonitis plus saline), 3 (OCP) and 4 (peritonitis plus OCP) were 3.30+/-0.94, 5.25+/-1.03, 1.12+/-0.83 and 0.28+/-0.48, respectively. Statistical analysis of adhesion scores revealed significant differences between groups, except between Groups 3 and 4 (p=0.265). Statistical analyses of grades of histopathological signs showed that Group 1 differed from Groups 2 and 4 (p=0.004, p=0.003, respectively); Group 2 differed from Groups 3 and 4 (p=0.001, p=0.001, respectively). On the other hand, differences between Group 3 and Groups 1 and 4 were not significant (p=0.06, p=0.08, respectively).


CONCLUSIONS
OCP decreased the peritoneal adhesion formation macroscopically and microscopically in the presence or absence of peritonitis. Peritoneal defects due to trauma are to be left open and OCP diluted 1:1 should not be used intraperitoneally.
Güzelsağaltici
Nihat
N
Department of General Surgery, School of Medicine, University of Dicle, Diyarbakir, Turkey.
Girgin
Sadullah
S
Gedik
Ercan
E
Büyükbayram
Hüseyin
H
Baç
Bilsel
B
D000818:Animals; D000891:Anti-Infective Agents, Local / Q000009:adverse effects / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005026:Ethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D007097:Imines; D008168:Lung / Q000187:drug effects / Q000473:pathology; D010532:Peritoneal Diseases / Q000209:etiology / Q000517:prevention & control*; D010533:Peritoneal Lavage; D010538:Peritonitis / Q000150:complications / Q000188:drug therapy*; D011183:Postoperative Complications / Q000517:prevention & control; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012128:Respiratory Distress Syndrome / Q000139:chemically induced / Q000473:pathology; D012996:Solutions; D000267:Tissue Adhesions / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome
D000891:Anti-Infective Agents, Local; D005026:Ethylene Glycols; D007097:Imines; D011725:Pyridines; D012996:Solutions; C005398:phenoxyethanol; C034213:octenidine